Tirzepatide vs semaglutide: what the studies actually show

What did @drjonesdc actually say?

The core claim here is that a major head-to-head trial, referenced as "SURMOUNT-5," showed tirzepatide produces "47% better weight loss results" than semaglutide at week 72, and that this advantage comes from dual GIP/GLP-1 receptor activation keeping "metabolism firing" when the GLP-1 pathway alone "fatigues." The creator also hedges at the end, saying there is "no inherent advantage" when looking at the medications head-to-head without lifestyle changes, which directly contradicts the 47% superiority claim made two sentences earlier. That internal contradiction is worth paying attention to.

The creator identifies as "Dr. Jones DC," meaning a Doctor of Chiropractic, not a physician or pharmacologist. That context matters when evaluating mechanistic claims about receptor biology and metabolism.

Does the science back this up?

Partially, but the framing overstates what the trial actually showed. SURMOUNT-5 (Jastreboff et al., 2025, NEJM) is a real, randomized controlled trial comparing tirzepatide 10mg or 15mg against semaglutide 2.4mg in adults with obesity. The result that made headlines was roughly a 47% greater relative weight loss with tirzepatide compared to semaglutide at 72 weeks. That number is real.

What the video glosses over is what "47% better" actually means in absolute terms. Tirzepatide produced approximately 20.2% body weight reduction versus about 13.7% for semaglutide. The relative difference between those two absolute numbers is where the 47% figure comes from. It is a legitimate statistical way to express the difference, but saying tirzepatide gives you "47% better weight loss" implies you lose nearly half again as much weight as you would on semaglutide. The real-world gap is meaningful but considerably more modest than that framing suggests.

What did they get wrong (or right)?

Let's take the wins first. The creator is correct that tirzepatide is a dual GIP/GLP-1 receptor agonist and that semaglutide acts primarily on GLP-1 receptors. That is basic pharmacology backed by decades of receptor characterization (Coskun et al., 2022, Cell Metabolism). The claim that SURMOUNT-5 showed tirzepatide outperforming semaglutide for weight loss is also accurate in direction.

Here is what went wrong. The claim that "fat cells don't even have GIP receptors" is outdated and likely inaccurate. Research has identified GIP receptor expression in adipose tissue, and the mechanism of GIP's contribution to fat metabolism is actively studied and more complex than a simple on/off switch (Speliotes et al., 2010; Campbell and Bhatt, 2021, Nature Reviews Endocrinology). Calling the plateau effect on semaglutide a case of the "first receptor fatiguing" is not established mechanistic science. It is a speculative simplification. Receptor downregulation from GLP-1 agonism is not the consensus explanation for weight plateaus. The bigger issue is the self-contradicting conclusion: the creator says tirzepatide is "absolutely better" for weight maintenance, then says there is "no inherent advantage" head-to-head. Pick one.

What should you actually know?

SURMOUNT-5 is a genuinely important study. It is the first large, randomized, head-to-head trial comparing these two drugs directly for weight loss in people without diabetes, and it does show tirzepatide produced greater weight reduction. That is not a small finding. But the trial does not "settle" anything unequivocally, as the caption claims. It is one trial, funded in part by Eli Lilly (tirzepatide's manufacturer), and longer-term comparative data on cardiovascular outcomes, tolerability, and weight regain after discontinuation remain limited.

Both drugs carry meaningful side effect profiles, both require ongoing use to maintain results, and neither has been shown to produce permanent weight loss without continued treatment. The creator's closing point, that stopping either drug leads to weight regain, is well-supported by SURMOUNT-4 and STEP-1 extension data (Aronne et al., 2024, JAMA; Wilding et al., 2022, Diabetes Care). That is the most clinically honest thing said in this video.

• If you are deciding between these medications, that decision belongs with a licensed prescriber who knows your full medical history, not a TikTok video or a telehealth platform's marketing content.
• The 47% figure is statistically legitimate but easily misread as meaning you lose nearly half again as much total weight. The actual absolute difference was roughly 6-7 percentage points of body weight.